OasisLMS

This webinar series was developed in support of the objectives of the AUA Clinical Trials Collective^TM. 

With the wide array of actively enrolling and forthcoming clinical trials for the treatment of advanced prostate cancer available to providers and patients, urologists newly or recently embarking on clinical trial research must be equipped with the skills to optimally select appropriate trials for implementation.  This webinar explores the critical questions that determine what makes a trial ideal, or suboptimal, for urology program and patient populations they serve.  Elements such as trial feasibility assessment, budgeting and negotiating, industry partnership, review board navigation, financial management, and protocol fundamentals will be discussed in this virtual educational activity, essential to all urologists considering enhancing their clinical practice with clinical trial research engagement.

Acknowledgements:

Support provided by an endowment from Chesapeake Urology Associates.

About the AUA Clinical Trials Collective™

The AUA Clinical Trials Collective™ (AUACTC™) was formed in 2024. The mission of the AUACTC™ is to address and overcome the challenges faced by clinical trials. This activity was developed in support of the educational needs identified by the AUACTC™. 

This continuing medical education activity was designed for:

• Residents/Fellows
• Urologists
• Clinical Research Coordinators
• Other Healthcare Professionals

After participating in this CME activity, participants will be able to:

1. Interpret the principles of designing and implementing feasibility assessments to match trial protocols with typical patient population, site capabilities, and strategic goals.
2. Strategically develop clinical trial budgets and navigate contract negotiation in partnership with trial sponsors.
3. Navigate institutional review broad processes and requirements to effectively implement and maintain desired clinical trial activation and enrollment timelines.
4. Initiate essential operational steps for trial startup, including staff training, protocol review, and site initiation.

Research Education, Conferences, and Communications Committee (RECCC) Disclosures:

RECCC Disclosures 7.22.25.pdf

Conflict of Interest Review Work Group Disclosures:

COI Review Workgroup DTL 2025.pdf

AUA Office of Research Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

AUA ACCREDITATION INFORMATION

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit^TM.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.